Introduction
Posterior Reversible Encephalopathy Syndrome (PRES), also known as reversible posterior leukoencephalopathy syndrome (RPLS), is a critical neurological condition demanding prompt clinical recognition and accurate diagnosis. Characterized by a constellation of symptoms including visual disturbances, seizures, severe headaches, and altered mental status, Pres Diagnosis hinges significantly on neuroimaging, particularly Magnetic Resonance Imaging (MRI). The hallmark of PRES on MRI is typically vasogenic edema predominantly affecting the parieto-occipital lobes. Early and accurate PRES diagnosis is crucial as timely intervention can reverse the condition and significantly improve patient outcomes, preventing potentially severe complications. This article provides an in-depth review of the clinical presentation, underlying causes, epidemiology, pathophysiology, diagnostic evaluation, differential diagnoses, treatment strategies, prognosis, and potential complications associated with PRES, emphasizing the critical aspects of PRES diagnosis. Furthermore, it highlights the essential roles of an interprofessional team in ensuring rapid recognition and effective management of PRES to enhance patient safety and optimize clinical outcomes.
Etiology and Risk Factors in PRES Diagnosis
Understanding the etiological factors is paramount in the clinical context of PRES diagnosis. Several conditions and triggers are associated with the development of PRES. Uncontrolled hypertension is a leading cause, often seen in acute hypertensive emergencies. Preeclampsia and eclampsia in pregnant women are also significant risk factors. Renal diseases, such as nephrotic syndrome and renal failure, contribute due to associated hypertension or electrolyte imbalances. Hepatic disorders can also predispose individuals to PRES.
Certain medications are strongly linked to PRES. These include various chemotherapy agents such as platinum-based drugs, gemcitabine, and regimens like CHOP/R-CHOP. Immunosuppressants, including tacrolimus, sirolimus, and interferon therapies, as well as targeted therapies and monoclonal antibodies like bevacizumab, pazopanib, sorafenib, and sunitinib, are also implicated. Autoimmune disorders such as hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, eosinophilic granulomatosis with polyangiitis, and systemic lupus erythematosus are recognized risk factors. Sepsis, irrespective of the source, is another critical systemic condition that can precipitate PRES.
While hypertension is the most frequently identified trigger, it’s important to note that PRES can occur even in the absence of significantly elevated blood pressure, particularly in cases related to cytotoxic or immunosuppressive medications. This underscores the multifactorial nature of PRES and the importance of considering a broad range of risk factors when pursuing a PRES diagnosis.
Epidemiology of PRES and Diagnostic Awareness
Historically, Posterior Reversible Encephalopathy Syndrome was likely underdiagnosed. However, with advancements in neuroimaging technology, particularly MRI, and increased clinical awareness, PRES diagnosis is becoming more frequent. This improved recognition has allowed for a better understanding of its epidemiology. PRES affects individuals across all age groups, but studies indicate a higher prevalence in middle-aged women.
A significant retrospective study analyzing 113 PRES patients by Fugate and colleagues revealed that a substantial portion (45%) had underlying autoimmune diseases. The most common presenting symptom was seizures (74%), followed by encephalopathy (28%), headache (26%), and visual disturbances (20%). This study highlighted that seizure presentation is a strong predictor for PRES diagnosis, with encephalopathy being the second most significant predictor. Furthermore, recent chemotherapy exposure and pre-existing renal failure were also identified as important clinical predictors, emphasizing the need for heightened vigilance in these patient populations to facilitate early PRES diagnosis.
Pathophysiological Mechanisms Underlying PRES Diagnosis
The precise pathophysiology of PRES is not fully elucidated, but current theories center around disruptions in cerebral autoregulation. Cerebral autoregulation is the brain’s intrinsic ability to maintain constant blood flow despite fluctuations in systemic blood pressure through vasodilation and vasoconstriction of cerebral vessels. In PRES, it is hypothesized that when systemic blood pressure exceeds the upper limit of autoregulation, typically around 160 mmHg systolic, cerebral blood flow increases passively. This hyperperfusion can lead to increased hydrostatic pressure, disrupting the blood-brain barrier (BBB) and causing leakage of intravascular fluid into the brain parenchyma, resulting in vasogenic edema.
The posterior circulation is thought to be more susceptible in PRES because it may have fewer adrenergic perivascular nerve fibers compared to the anterior circulation, potentially leading to less effective autoregulation. However, the hypertension-hyperperfusion hypothesis does not explain all cases, as PRES can occur in normotensive patients, especially those on cytotoxic drugs like tacrolimus. This suggests that endothelial dysfunction is another critical pathophysiological mechanism. Drugs like tacrolimus, cyclosporine, and cisplatin can directly damage the endothelium, compromising the BBB and leading to edema formation independent of blood pressure levels.
Another proposed mechanism involves ischemia due to dysregulated autoregulation leading to vasoconstriction and cytotoxic edema. While some radionuclide studies have shown vasoconstriction, this is not a consistent finding, and pathological studies have largely failed to demonstrate evidence of ischemia or infarction in PRES. Furthermore, inflammatory processes and endothelial activation in conditions like sepsis, autoimmune disorders, and metabolic derangements can also increase BBB permeability, contributing to vasogenic edema and the potential for PRES development. These multiple potential pathways highlight the complexity of PRES pathophysiology and emphasize that PRES diagnosis should consider various underlying mechanisms.
Clinical Presentation and History Crucial for PRES Diagnosis
A thorough clinical history and physical examination are indispensable for PRES diagnosis, as it is fundamentally a clinicoradiological diagnosis. The clinical manifestations of PRES are diverse, varying in severity and onset. Headache is a common symptom, reported in about 50% of cases. Encephalopathy, manifesting as altered mental status, confusion, or lethargy, is seen in approximately 28% of patients. Visual disturbances are also frequent (around 39%), encompassing a range of symptoms such as binocular diplopia, vision loss (including cortical blindness and no light perception), hemianopia, and quadrantanopia. Seizures are a prominent feature, occurring in up to 80% of cases, and can be focal or generalized tonic-clonic seizures. Focal neurological deficits are less common, present in 10-15% of patients.
Given that patients may present with altered mental status, obtaining a detailed history directly from the patient may not always be feasible. Therefore, collateral history from family members, friends, or caregivers is crucial. While hypertension is commonly associated with PRES, it is not universally present. Up to 75% of patients may have moderate to severe hypertension upon presentation, but a significant minority can be normotensive. It’s postulated that the rapidity of blood pressure elevation, rather than the absolute value, might be a critical factor, similar to the pathophysiology of febrile seizures in children.
During physical examination, specific neurological findings should be carefully assessed. These include visual field defects (hemianopia, quadrantanopia, visual neglect), cortical blindness, horizontal gaze palsy with an intact vestibulo-ocular reflex, and papilledema. Signs of recent seizures, such as oral trauma from tongue biting, brisk reflexes, active convulsions, and urinary or fecal incontinence, should also be noted. These clinical findings, in conjunction with risk factors and neuroimaging, are essential for accurate PRES diagnosis.
Diagnostic Evaluation: Imaging and Ancillary Tests for PRES Diagnosis
Neuroimaging is the cornerstone of PRES diagnosis. While clinical symptoms are suggestive, they are not sufficient for definitive diagnosis. A head Computed Tomography (CT) scan is often the initial imaging modality, primarily to rule out acute neurological emergencies such as intracranial hemorrhage, which can present similarly with altered mental status, headache, and seizures.
However, MRI of the brain without contrast is the preferred imaging modality for PRES diagnosis. MRI is highly sensitive in detecting vasogenic edema, the pathological hallmark of PRES. On MRI, vasogenic edema appears as hyperintense signals on T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) sequences. The characteristic distribution is in the parieto-occipital lobes, but other regions can be involved, including the frontal lobes (especially the superior frontal gyri), temporal lobes, cerebellum, brainstem, and deep white matter. Although classically posterior, atypical distributions are increasingly recognized, highlighting that the absence of posterior predominance does not exclude PRES diagnosis. The cortex is often more involved than the white matter, possibly due to its denser cellular structure which may resist edema accumulation. MRI also aids in differentiating PRES from other conditions in the differential diagnosis, such as hypoxic-ischemic encephalopathy, posterior circulation stroke, and primary central nervous system vasculitis.
In cases involving the posterior cerebral hemispheres, it’s crucial to differentiate PRES from posterior cerebral artery (PCA) infarction. In PRES, there is typically sparing of the calcarine and paramedian occipital lobes, which are commonly affected in PCA infarcts. Diffusion-Weighted Imaging (DWI) is also valuable in distinguishing PRES from stroke. In PRES, DWI findings are typically hypo- or isointense, reflecting vasogenic edema, whereas stroke typically shows hyperintense signals on DWI due to cytotoxic edema.
Vascular imaging, including Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA) of the brain, is usually normal in PRES. However, these may be performed to exclude other conditions, such as CNS vasculitis, where vasoconstriction or vasodilation patterns might be observed. Magnetic Resonance Venography (MRV) can be used to rule out cerebral venous sinus thrombosis, another differential diagnosis.
Beyond imaging, laboratory investigations are crucial to identify underlying etiologies contributing to PRES diagnosis. Blood work should include electrolytes to assess for imbalances like uremia and hypomagnesemia, as well as albumin levels to detect hypoalbuminemia and protein deficiencies. Cerebrospinal fluid (CSF) analysis may be indicated, especially in immunocompromised patients or when infection is suspected, to rule out encephalitis (e.g., herpes simplex encephalitis). Blood glucose levels should be checked to exclude hypoglycemia. Electroencephalography (EEG) can be helpful, particularly if there is persistent altered mental status without overt seizures, to detect subclinical seizure activity. However, EEG findings in PRES are generally non-specific and are not diagnostic. A comprehensive diagnostic approach integrating clinical findings, risk factor assessment, neuroimaging, and relevant laboratory tests is essential for accurate PRES diagnosis and management.
Treatment and Management Strategies Following PRES Diagnosis
Once PRES diagnosis is confirmed, the immediate focus shifts to identifying and managing the underlying cause and carefully controlling hypertension, if present. There is no standardized antihypertensive protocol specifically for PRES. However, treatment is generally recommended when blood pressure exceeds 160/110 mmHg, with a target reduction to 130-150/80-100 mmHg. It is crucial to avoid rapid blood pressure reduction, as this can lead to cerebral hypoperfusion and potentially worsen ischemia. Blood pressure should be decreased gradually, not exceeding a 25% reduction in the initial presenting blood pressure within the first six hours.
Due to the need for careful blood pressure titration, especially in the acute phase, admission to an intensive care unit (ICU) may be necessary. Intravenous (IV) titratable antihypertensives like nicardipine, clevidipine, or labetalol are often used to achieve and maintain the target blood pressure. After the acute phase, transitioning to oral antihypertensive medications for continued blood pressure management is indicated. The duration of antihypertensive treatment post-acutely is not definitively established and should be individualized.
Seizures are a common and potentially serious complication of PRES. While there is no specific antiepileptic drug regimen for PRES-related seizures, common anticonvulsants such as levetiracetam and phenytoin are frequently used. Antiepileptic treatment is typically initiated during the acute phase of PRES and may be discontinued once PRES resolves and seizures are controlled. However, in some cases, epilepsy may develop as a complication, requiring long-term antiepileptic therapy.
Corticosteroids have been proposed for PRES due to their potential to reduce vasogenic edema. However, clinical evidence supporting their efficacy is lacking, and case reports even suggest corticosteroids might trigger PRES in some patients. Therefore, corticosteroids are not generally recommended for the routine management of PRES. If PRES is associated with immunosuppressive or cytotoxic agents like bevacizumab, pazopanib, sorafenib, or sunitinib, dose reduction or discontinuation of these agents should be considered. Effective treatment and management of PRES necessitate addressing the underlying etiology, cautious blood pressure control, seizure management, and careful consideration of medication adjustments.
Differential Diagnosis in PRES Diagnosis
The differential diagnosis for PRES is broad, as many conditions can mimic its clinical and radiological features. It is essential to consider and exclude these alternatives to ensure accurate PRES diagnosis and appropriate management. Key differential diagnoses include:
- Intracranial Hemorrhage: Subarachnoid hemorrhage, subdural hemorrhage, and intraparenchymal hemorrhage can present with acute neurological symptoms similar to PRES. CT head is crucial to rule out hemorrhage.
- Cerebral Venous Sinus Thrombosis (CVST): CVST can cause headache, seizures, and altered mental status, and may sometimes show edema on MRI, necessitating MRV to exclude.
- Posterior Circulation Ischemic or Hemorrhagic Stroke: Stroke, particularly in the posterior circulation, can mimic PRES. DWI on MRI is critical to differentiate, as stroke typically shows cytotoxic edema while PRES shows vasogenic edema.
- Basilar Artery Thrombosis: A severe form of posterior circulation stroke, basilar artery thrombosis requires immediate recognition and intervention.
- Encephalitis: Both infectious (e.g., HSV encephalitis) and autoimmune encephalitis can cause altered mental status, seizures, and imaging abnormalities. CSF analysis is vital to exclude encephalitis.
- Uremic Encephalopathy: In patients with renal failure, uremic encephalopathy can present with similar neurological symptoms. Blood work to assess renal function is necessary.
- Hypoglycemia: Metabolic encephalopathy due to hypoglycemia can cause altered mental status and seizures, requiring blood glucose measurement for exclusion.
A systematic approach, incorporating clinical evaluation, neuroimaging (especially MRI with DWI), and appropriate ancillary tests, is essential to differentiate PRES from these and other mimicking conditions and to arrive at an accurate PRES diagnosis.
Prognosis and Long-Term Outcomes Following PRES Diagnosis
The prognosis for PRES is generally favorable if the condition is promptly recognized and treated. Symptom improvement or complete resolution typically occurs within days to weeks following appropriate management. Visual symptoms often fully resolve, particularly with early intervention. However, some patients may experience residual visual deficits, though these usually improve over 3 to 4 months. It remains unclear why some individuals have prolonged visual or neurological sequelae. Delayed treatment and extensive cerebral vasogenic edema can worsen the prognosis, as increased pressure can compromise cerebral blood flow, potentially leading to ischemia and irreversible damage. Brainstem involvement is also associated with a poorer prognosis.
Recurrence of PRES is possible, particularly in individuals with predisposing conditions, such as those undergoing dialysis. Long-term complications, although infrequent with timely treatment, can include persistent neurological deficits, epilepsy, and in severe cases, life-threatening conditions such as transforaminal cerebellar herniation. Early PRES diagnosis and management are crucial to minimize the risk of these complications and optimize patient outcomes.
Complications of Untreated or Delayed PRES Diagnosis
If PRES diagnosis and treatment are delayed or inadequate, several serious complications can arise. Focal neurological deficits due to ischemic injury can become permanent. Epilepsy is a potential long-term sequela. Life-threatening complications include transforaminal cerebellar herniation, a particularly grave outcome reported in children, especially following hematopoietic stem cell transplantation. These severe complications underscore the critical importance of early recognition, accurate PRES diagnosis, and prompt therapeutic intervention to prevent irreversible neurological damage and improve patient survival.
Deterrence, Patient Education, and Healthcare Team Collaboration for Improved PRES Diagnosis and Outcomes
Preventive strategies and patient education play a crucial role in reducing the incidence and improving outcomes in PRES. Raising awareness among healthcare providers and at-risk patient populations about PRES risk factors and early symptoms is paramount. Patient education on blood pressure management is essential, particularly for individuals with hypertension or preeclampsia risk, to minimize the likelihood of cerebral autoregulation dysfunction that can lead to PRES. Similarly, educating patients and providers about the potential neurotoxic effects of cytotoxic and immunosuppressant medications, even in the absence of hypertension, can promote vigilance and early recognition of PRES in these settings.
Enhancing healthcare team outcomes in PRES management relies heavily on effective interprofessional communication and collaboration. Given the diverse clinical presentations of PRES and the need for prompt and accurate PRES diagnosis using neuroimaging (especially MRI), teamwork is essential. This includes physicians from neurology, critical care, radiology, pharmacy practitioners, nurses, technicians, and therapists. Radiologists play a vital role in recognizing key imaging findings suggestive of PRES. Neurologists and critical care specialists collaborate closely in managing blood pressure, seizures, and other complications, often in the ICU setting. Pharmacists contribute to medication management and ensuring appropriate drug dosing and adjustments. Nurses are critical in monitoring patients, administering medications, and providing continuous care. Effective communication, shared decision-making, and a collaborative approach are key to timely PRES diagnosis and management, leading to improved patient safety, quality of care, and neurological outcomes. An integrated care pathway, combining evidence-based practices and interprofessional collaboration, is essential for optimizing patient care in PRES.
Review Questions
[Link to review questions in original article]
References
[List of references as in original article]
Disclosure: Jaime Zelaya declares no relevant financial relationships with ineligible companies.
Disclosure: Lama Al-Khoury declares no relevant financial relationships with ineligible companies.
